agenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product, shows anti-tumor activity

**Background**

iNKT cells target tumor cells and reshape the TME

- Direct Tumor Targeting
- Reducing of the TME

**INKT cells can target tumor cells through:**
- The invariant T cell receptor (iTCR), which detects glycolipids presented by CD1d
- NCiD2, which detects stress ligands expressed on tumor cells

**Direct Tumor Targeting**

**Results**

iNKT cells efficacy against the Nalm6-CD1d cells were tested in vitro.

**iNKT cell-based allogeneic cell therapy offers improved benefits over other cell formats**

**Conclusions**

- **MiNK Therapeutics** is a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
- **MiNK Therapeutics** delivered 3 INDs for lead product candidate (agenT-797) targeting hem malignancies (multiple myeloma, solid tumors and ARDS secondary to COVID-19 infection).
- We developed murine xenograft models to address the impact of agenT-797 in liquid and solid tumors, demonstrating trafficking, activation and expansion of these cells in response to different tumors.

**Correspondence**

Marc High, Chief Science Officer, MiNK Therapeutics
marc.high@miinktherapeutics.com

Presented at The Society for Immunotherapy of Cancer (SITC), November 30 - 10, 2021